ACHRONIX:

Achronix Unveils 120 Gbps Reprogrammable Networking System

Achronix Demonstrates 1066 Mbps DDR3 Reference Design On New Speedster Plug-in Card Development Board

Achronix Taps Signali for 10/40/100 Gbps Encryption IP in World's Fastest FPGAs

Achronix Establishes Distribution Channels in Europe and Israel to Meet Growing Demand for its Speedster 1.5 GHz FPGAs

Achronix Named Finalist of Prestigious 2009 EE Times ACE Award for Startup of the Year

Achronix and Mentor Graphics Announce Joint Agreement

Achronix to Demonstrate Speedster FPGA's 10.3 Gbps SerDes

eSilicon Delivers 65nm Silicon and Package to Achronix

Achronix Completes First Close of $52 Million Series B Preferred Stock Financing

ViASIC's Place and Route Technology Chosen by Achronix Semiconductor

Verific's Netlist-Only Parser Used in Achronix CAD Environment

Achronix Semiconductor Launched to Break Through FPGA Performance Barriers

BAE Systems Signs Agreement with Achronix to Develop High Performance Radiation-Hardened Reconfigurable FPGA

Industry Veteran Dan Elftmann Joins Achronix Semiconductor as Director of Strategic Marketing for Industrial, Military and Aerospace Markets

Achronix and Mentor Graphics Announce Joint Venture

Achronix Completes $25.4 Million Series A Preferred Stock Financing

SEAHORSE BIOSCIENCE:

Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference

New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers.

SeahorseXF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG DISCOVERY at 2009 Molecular Medicine Conference

Seahorse BioScience, Inc. acquires BioProcessors Corp.

BioProcessors Announces Appointment of Scott D'Amour as President

Industry Veteran Jonathan Rennert Joins BioProcessors Corporation as President and CEO

Invitrogen Adds Capabilities to PD-Direct™ Services with SimCell™ Technology

HLM Venture Partners Announces Investment in BioProcessors Corporation

BioProcessors' SimCell™ Platform Selected by Novo Nordisk

BioProcessors' SimCell™ Platform Demonstrates Potential to Increase Amgen's Cell Culture Experiment Capacity

BIOVEX:

BIOVEX AGREES SPA WITH THE FDA FOR A PIVOTAL PHASE III STUDY WITH ONCOVEXGM-CSF IN HEAD AND NECK CANCER

Biovex to Announce Updated Survival Data from a Phase II Clinical Study of ONCOVEXGM-CSF in Metastatic Melanoma at the 2009 Amerian Society of Clinical Oncology Meeting

Biovex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer with ONCOVEXGM-CSF at the 2009 American Society of Clinical Oncology Meeting

BioVex Commences OncoVex Phase 3 Trial in Metastatic Melanoma

BioVex Raises $40MM in First Close of Series F Financing

BIOVEX ANNOUNCES REGULATORY CLEARANCE TO COMMENCE A CLINICAL STUDY WITH immunoVEX, A VACCINE CANDIDATE FOR GENITAL HERPES

BIOVEX REPORTS POSITIVE PHASE II TRIALS OF ONOCOVEX AT ASCO

BIOVEX TO REPORT PHASE II TRIALS OF ONCOVEX AT ASCO

BIOVEX AGREES SPA WITH THE FDA FOR PIVOTAL STUDY WITH OncoVEX IN ADVANCED METASTATIC MELANOMA; ANNOUNCES PRESENTATION OF PHASE 11 RESULTS AT ASCO

BIOVEX PRESENTS AT JPMORGAN 26TH ANNUAL CONF.

BIOVEX RAISES $22 MILLION IN FIRST CLOSE OF SERIES E FINANCING

BIOSCALE:

News will be posted as it becomes available.

BORO NETWORKS:

News will be posted as it becomes available.

CELLERATION:

Celleration Appoints Mark T. Wagner President and Chief Executive Officer

Celleration President and CEO Kevin Nickels to Participate on AdvaMed CEO Advisory Council

Study Shows Celleration® MIST Therapy Expedites Wound Healing

Celleration® Appoints Christopher Geyen CFO

Celleration® Appoints Sven Wehrwein to Board of Directors

Celleration® Appoints Michael R. Kujak Vice President of Marketing

Celleration® Completes $30 Million Financing - Proceeds to Fund Expansion of Celleration's Commercialization Efforts

Celleration® announces the publication of a new educational grant-funded series “MIST Therapy® System – Thoughts on Therapy.” March 13, 2007

Celleration, Inc. announces the publication of a clinical study: Effectiveness of MIST Therapy for the Healing of Chronic Wounds. Dr. Ennis. October 23, 2006

Celleration, Inc. receives 2005 Tekne Award for Emerging Biotechnology Company. November 17, 2005

Celleration, Inc. receives $20.6 Million in Series C Funding. November 1, 2005

Celleration, Inc. announces the Publication of a clinical study: Efficacy of MIST Therapy for the Treatment of Diabetic Foot Ulcers. Dr. Ennis. August, 29 2005

CEPTION THERAPUTICS:

Cephalon Signs Option Agreement to Acquire Ception Therapeutics

Ception to Participate in the Private Company Forum at 29th Annual Goldman Global Healthcare Conference

Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children

Suketu Desai, Ph.D., and James A. Dowell, Ph.D. Join Ception Therapeutics

Ception Therapeutics Raises Additional $14.7 Million Bringing Total Series C Financing to $77 Million

Patricia A. Cleveland Joins Ception Therapeutics as Vice President of Regulatory Affairs

Ception Therapeutics Raises $63 Million in Series C Financing

CHIMEROS:

News will be posted as it becomes available

K2M:

K2M Launches NATURAL BRIDGE Low Profile Transverse Connectors

K2M ALEUTIAN Spacer Systems Receive FDA Clearance to be Marketed as Intervertebral Body Fusion Devices

K2M Launches CASPIAN Spinal System to Address Cervico-Thoracic Pathologies

K2M President and CEO Named Ernst and Young Entrepreneur of the Year in Greater Washington Region

K2M Debuts Next Generation Biomaterial at 2009 Spine Arthroplasty Society Meeting

K2M Addresses High Demand for Treating Complex Cervico-Thoracic Pathologies

K2M Receives 510(k) Clearance for its tifix® CAYMAN Plate Systems

K2M Introduces A Simplified Minimally Invasive Surgical Technique for Dynamic Stabilization of the Spine

K2M Obtains Worldwide Exclusive Rights to Revolutionary Injectable Polymer Technology for Treatment of Spinal Disorders

K2M Enters the Biomaterials Sector of the Spinal Market

K2M Names Gregory Cole as Chief Financial Officer

K2M Continues Facility Expansion

K2M Enters the International Spine Market

K2M Launches RANGE Rigid Rod (R2 Rod) for Complex Procedures

ASCEND Hosts 3rd Annual Meeting of Controversies in Contemporary Spine Surgery

K2M Launches ALEUTIAN AN and Anterior Lumbar Spacer Systems

K2M Launches SERENGETI Minimally Invasive Retractor System

K2M Announces Phase II Launch of PYRENEES Cervical Plate System

K2M Announces the RANGE Spinal System for Complex Spine Cases

K2M Redefines Spine Surgery with the SERENGETI Minimally Invasive Retractor System

K2M Completes 500th Surgery with MESA Spinal System

Tom Patton Joins K2M Board

K2M Launches MESA Spinal System

K2M Launches DENALI Deformity Spine Technology

K2M Closes $21.5 Mezzanine Round Led By Ferrer Freeman and Co.

CONOR MEDSYSTEMS:

Conor Medsystems Stockholders Approve Merger Agreement with Johnson and Johnson

FLOWCARDIA:

FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer

FlowCardia Appoints Deborah DeFilippo CFO

December 11, 2007 - FlowCardia, inc. Launches Peripheral CROSSER Catheter Portfolio in the US

December 5, 2007 - Chris Barys Appointed Senior VP, Sales

September 5, 2007 — FlowCardia, Inc. Announces Final Enrollment in the PATRIOT Peripheral Study with the CROSSER™ Family of CTO Recanalization Catheters

August 30, 2007 — FlowCardia, Inc. Raises $30 Million in Series C Financing

January 25, 2007 — FlowCardia, Inc. Announces Availability of the Peripheral CROSSER™ Catheter Portfolio in Europe — A New, Endovascular Option to Amputation and Bypass Surgery

January 23, 2007 — FlowCardia, Inc. Announces 510(k) Clearance for the CROSSER™ 14 Chronic Total Occlusion Recanalization System — A New, Minimally Invasive Option to Bypass Surgery

IKONISYS:

Ikonisys to Present at the Thomas Weisel Partners Healthcare Conference 2009

Ikonisys to Present at the J.P. Morgan 27th Annual Healthcare Conference

Ikonisys Receives FDA Clearance for Non-Invasive, HER-2 Breast Cancer Test

Ikonisys Reports Positive Results from Clinical Study Designed to Evaluate the Efficacy of Circulating Tumor Cell Detection with Ikonisys' Automated Microscope

Ikonisys to Present at AdvaMed 2008: The MedTech Conference

Ikonisys Introduces Rare-Cell Test Designed to Determine Early Progression to Cervical Cancer

Ikonisys to Present at UBS Global Life Sciences Conference

Ikonisys Appoints Louise A. Mawhinney, CPA as Senior Vice President and Chief Financial Officer

Ikonisys Receives CMS Registration to Establish Clinical Laboratory for Proprietary, Rare-Cell Based Tests

Ikonisys Begins Clinical Trial for Early, Non-Invasive Testing of Downs Syndrome

LIGHT SCIENCES ONCOLOGY:

Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine™ for Prostate Conditions with Start-Up of Phase 2 BPH Trial

First Pediatric Patient Treated with Aptocine™, a Novel Light-Activated Drug, in Neurofibromatosis Study

Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine™, a Novel Light-Activated Drug Therapy for Cancer

Light Sciences Oncology Elects Former FDA Commisioner Frank Young, M.D., Ph.D., to Board of Directors

Light Sciences Oncology Completes Patient Enrollment in Phase III Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma

Light Sciences Oncology Raises $40.1 Million in Series C Financing

LSO Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate

LSO Appoints David Holveck to Board

Light Sciences Oncology Initiates Phase III Trial of Its Light Infusion Therapy (Litx(TM)) in Patients with Metastatic Colorectal Cancer

Light Sciences Oncology Completes $30 Million Series B Private Financing

Light Sciences Oncology Initiates Phase II Trial of Litx™ Therapy in Patients with Glioma

Light Sciences Oncology Receives Special Protocol Assessment for Pivotal Phase III Trial of Litx™ Therapy in Metastatic Colorectal Cancer

Light Sciences Oncology Purchases the Assets of its Former Parent Company Light Sciences LLC in Equity Transaction

Light Sciences Oncology Completes Second Closing in $67 Million Financing for Late Stage Development of Litx™ and Announces Additional Directors

LSO Completes $35 Million Financing for Late Stage Development of Litx

LSO Announces Progress in Liver Cancer Trials

OXYRANE:

News will be posted as it becomes available

PAYZY:

News will be posted as it becomes available

SYMPHOGEN:

Symphogen Appoints Adriann Sax Chief Business Officer

Symphogen and Origen Collaborate to Produce Transgenic Chicken for Generation of Fully Human Antibody Therapeutics

Symphogen Secures $44 Million Financing to Support Clinical Development of Antibody Products

Symphogen Acquires Receptor BioLogix's Technology

Newly Published Preclinical Study Shows Receptor BioLogix's Pan-HER Ligand Trap Has Broad Anti-Cancer Activity

Receptor BioLogix Names Veteran Life Sciences Executive Dale R. Pfost As Chief Executive Officer

Pioneers of Targeted Breast Cancer Therapy Win Nineteenth Annual Warren Alpert Foundation Prize. BOSTON, May 30, 2007

RF ARRAYS:

Rf Arrays, Inc Receives 2009 Best of Milpitas Award

RF Arrays, Inc. Delivers World's Smallest Zigbee(R) Optimized Integrated Front End

RF Arrays, Inc. Delivers World's Smallest Wi-Fi Integrated Front End

Design Partner for Jennic Ltd.

Design Partner for Nordic Semiconductors

SILICON SPACE TECHNOLOGIES:

News will be posted as it becomes available

LIGHTWIRE:

Lightwire Introduces Production-Ready 10 Gbps CMOS Photonics Technology, Defines Roadmap to 100 Gbps and Beyond

Lightwire Introduces First CMOS Photonics 10GbE SFP+ LRM Optical Module

Lightwire, IME and Chartered move to production

SiOptical becomes Lightwire

THEROX:

Therox Raises $30 Million in Preferred Equity Financing

THEROX AMIHOT II Pivotal Trial Meets Endpoints

THEROX Announces Completion of Pivotal Trial

XOFT:

Xoft Expands Cancer Treatment Platform with Launch of Skin Cancer Electronic Brachytherapy Trial at AAPM Meeting

First Skin Cancer Patients Treated with Electronic Brachytherapy (eBx) at University of Wisconsin Riverview Cancer Center

FDA Clears New Skin and Surface Treatment Applicator for Use With Xoft's Axxent® Electronic Brachytherapy (eBx) System

Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium

XOFT TO PRESENT AT THE CITI INVESTMENT RESEARCH RADIATION ONCOLOGY CONFERENCE

XOFT SECURES $25 MILLION IN ADDITIONAL FUNDING FOR AWARD-WINNING ELECTRONIC BRACHYTHERAPY TECHNOLOGY

ELECTRONIC BRACHYTHERAPY ACCURATELY DELIVERS NON-RADIOACTIVE THERAPY DIRECTLY TO BREAST ENDOCAVITY CANCER SITES

R AND D MAGAZINE SELECTS AXXENT® MINIATURE BRACHYTHERAPY X-RAY SOURCE AS ONE OF THE 100 MOST TECHNOLOGICALLY SIGNIFICANT PRODUCTS OF THE PAST YEAR

FROST AND SULLIVAN HONORS XOFT FOR ONCOLOGY INNOVATION

FIRST BREAST CANCER PATIENT RECEIVES TREATMENT IN NATIONAL ELECTRONIC BRACHYOTHERAPY REGISTRTY LAUNCHED BY THREE PHYSICIAN SOCIETIES

FDA CLEARS NEW APPLICATIONS FOR ENDOMETRIAL CONACER TREATMENT WITH AXXENT

RESEARCH PRESENTED AT ABS FURTHER VALIDATES USE OF ELCTRONIC BRACHYTHERAPY

XOFT MEDICAL DIRECTOR RECOGNIZED BY GOTHAM PRIZE

FDA CLEARS EXPANDED USE OF XOFT’S AXXENT® ELECTRONIC BRACHYTHERAPY SYSTEM FOR ALL RADIATION THERAPY INDICATIONS

XOFT TO PRESENT AT THE 26TH ANNUAL JPMORGAN HEALTHCARE CONFERENCE

AMERICAN MEDICAL ASSOCIATION APPROVES CPT CODE FOR ELECTRONIC BRACHYTHERAPY FOR TREATMENT OF EARLY BREAST CANCER

XOFT REACHES MILESTONE AS AXXENT® ELECTRONIC BRACHYTHERAPY SYSTEM IS USED TO TREAT EARLY STAGE BREAST CANCER PATIENTS

Axxent® Electronic Brachytherapy System from Xoft Offers Patients with Early Stage Breast Cancer a New Option to Reduce Recurrence of Disease

Xoft, Inc., Announces Additional Funding for Breakthrough Electronic Brachytherapy Technology